Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis

  06 January 2021

The proportion of patients infected with SARS-CoV-2 that are prescribed antibiotics is uncertain, and may contribute to patient harm and global antibiotic resistance. Our objective was to estimate the prevalence and associated factors of antibiotic use in patients with confirmed COVID-19.

Three-quarters of patients with COVID-19 receive antibiotics, prescribing is significantly higher than the estimated prevalence of bacterial co-infection. Unnecessary antibiotic use is likely high in patients with COVID-19.


Author(s): Bradley J. Langford, PharmD Miranda So, PharmD Sumit Raybardhan, BScPhm MPH Valerie Leung, BScPhm MBA Jean-Paul R. Soucy, MSc Duncan Westwood, BA Nick Daneman, MD, MSc Derek R. MacFadden, MD, ScD
Effective Surveillance   Healthy Animals  


Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition


JSS University


Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!